Pixantrone beyond monotherapy: a review

Outcomes for patients with non-Hodgkin’s lymphoma (NHL) that proves refractory to treatment remain poor. Treatment of such patients is individualized and can include enrolment in a clinical trial of novel agents or use of one of a wide array of drug regimens. Initial treatment with anthracyclines su...

Descripción completa

Detalles Bibliográficos
Autores principales: Barrenetxea Lekue, Cristina, Grasso Cicala, Silvina, Leppä, Sirpa, Stauffer Larsen, Thomas, Herráez Rodríguez , Susana, Alonso Caballero, Clara, Jørgensen, Judit M., Toldbod, Helle, Leal Martínez, Irene, D’Amore, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700039/
https://www.ncbi.nlm.nih.gov/pubmed/31312929
http://dx.doi.org/10.1007/s00277-019-03749-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700039/
https://www.ncbi.nlm.nih.gov/pubmed/31312929
http://dx.doi.org/10.1007/s00277-019-03749-0

Ejemplares similares